United Therapeutics (UTHR) - Stock Price & Dividends

United Therapeutics Corporation, traded as UTHR on NASDAQ, is a biotechnology company focusing on developing and marketing products to help patients battling chronic and life-threatening illnesses worldwide, not limited to the United States.

The company offers a range of commercial therapies such as Remodulin, Tyvaso, Tyvaso DPI, Remunity Pump, Orenitram, Unituxin, and Adcirca, aimed at easing symptoms and improving the quality of life for patients with conditions like pulmonary arterial hypertension and neuroblastoma.

Moreover, United Therapeutics Corporation is actively involved in ongoing research and development, including projects like RemoPro, Ralinepag, Aurora-GT for gene therapy, and TETON studies focusing on idiopathic pulmonary fibrosis treatment.

Collaborations with entities like DEKA Research, MannKind Corporation, and Arena Pharmaceuticals highlight the company's commitment to innovation and improving treatment options for a wide range of medical conditions.

The company, headquartered in Silver Spring, Maryland, was established in 1996 and continues to strive towards making a meaningful impact in the field of biotechnology and healthcare. For more information, visit https://www.unither.com.